Xenetic reports Q1 EPS (78c) vs. (56c) last year

Reports revenue $510,817 vs. $605,844 last year. “We have initiated several preclinical studies on the influence of DNase in combination with standard treatment paradigms such as chemotherapy or immune checkpoint blockade and expect to present results in the second half of this year. We anticipate that this growing body of data will have an important impact in demonstrating the promise of incorporating DNase into clinical treatment regimens for certain solid tumors, and in guiding our clinical development strategy,” commented, Jeffrey Eisenberg, CEO of Xenetic. “We believe we have successfully positioned 2024 to be a year of meaningful preclinical data and remain focused on executing our plans to advance development towards our first in human trial.